{
    "id": 29361,
    "fullName": "PTPN11 loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "PTPN11 loss indicates loss of the PTPN11 gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5781,
        "geneSymbol": "PTPN11",
        "terms": [
            "PTPN11",
            "BPTP3",
            "CFC",
            "JMML",
            "METCDS",
            "NS1",
            "PTP-1D",
            "PTP2C",
            "SH-PTP2",
            "SH-PTP3",
            "SHP2"
        ]
    },
    "variant": "loss",
    "createDate": "02/18/2019",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16036,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CRISPR-Cas9-mediated knock-out of PTPN11 abolished reactivation of MAPK signaling in the presence of Mekinist (trametinib) in pancreatic ductal adenocarcinoma cells harboring KRAS G12V, resulted in enhanced growth inhibition in culture (PMID: 29808009).",
            "molecularProfile": {
                "id": 31379,
                "profileName": "KRAS G12V PTPN11 loss"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14154,
                    "pubMedId": 29808009,
                    "title": "Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29808009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16035,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CRISPR-Cas9-mediated knock-out of PTPN11 abolished reactivation of MAPK signaling in the presence of Selumetinib (AZD6244) in pancreatic ductal adenocarcinoma cells harboring KRAS G12V in culture, resulted in enhanced growth inhibition (PMID: 29808009).",
            "molecularProfile": {
                "id": 31379,
                "profileName": "KRAS G12V PTPN11 loss"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14154,
                    "pubMedId": 29808009,
                    "title": "Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29808009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16039,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CRISPR-Cas9-mediated knock-out of PTPN11 abolished reactivation of MAPK signaling in the presence of Selumetinib (AZD6244) in pancreatic ductal adenocarcinoma cells harboring KRAS G12D, resulted in enhanced growth inhibition in culture (PMID: 29808009).",
            "molecularProfile": {
                "id": 31380,
                "profileName": "KRAS G12D PTPN11 loss"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14154,
                    "pubMedId": 29808009,
                    "title": "Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29808009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16040,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CRISPR-Cas9-mediated knock-out of PTPN11 abolished reactivation of MAPK signaling in the presence of Mekinist (trametinib) in pancreatic ductal adenocarcinoma cells harboring KRAS G12D, resulted in enhanced growth inhibition in culture (PMID: 29808009).",
            "molecularProfile": {
                "id": 31380,
                "profileName": "KRAS G12D PTPN11 loss"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14154,
                    "pubMedId": 29808009,
                    "title": "Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29808009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31378,
            "profileName": "PTPN11 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31379,
            "profileName": "KRAS G12V PTPN11 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31380,
            "profileName": "KRAS G12D PTPN11 loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}